Amgen Bets $45m Plus Up To $1.7bn On Xencor's Bi-Specifics

Amgen's Blincyto (blinatumumab) was the first US FDA-approved bi-specific antibody and now the biotechnology giant may spend nearly $1.75bn on bi-specifics developed with Xencor Inc.'s XmAb platform for monoclonal antibodies that bind to two separate targets.